Back to search resultsSummaryRMgm-888
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 23638681 Reference 2 (PMID number) : 27084458 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | P. berghei ANKA 2.34 |
Other information parent line | P. berghei ANKA 2.34 is a cloned, gametocyte producer line of the ANKA strain (PubMed: PMID: 15137943). |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | K. Frénal, J.Rayner, O. Billker, E. Bushell, D. Soldati-Favre |
Name Group/Department | Malaria Programme |
Name Institute | Wellcome Trust Sanger Insitute |
City | Cambridge Hinxton |
Country | UK |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-888 |
Principal name | PbDHHC3 _KO |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Not tested |
Fertilization and ookinete | Normal ookinete production. (Light microscope)morphology of mature ookinetes is normal. (Slightly) reduced motility of mutant ookinetes |
Oocyst | Reduced (10 fold) oocyst production |
Sporozoite | Reduced number (4-fold) of hemolymph sporozoites Reduced number (25-fold) of salivary gland sporozoites. Gliding motility of salivary gland mutant sporozoites is severely impaired, with only 10% of sporozoites producing trails |
Liver stage | Mice injected with 5,000 or 10,000 hemolymph sporozoites of the mutant failed to develop blood-stage parasitemia. Mice inoculated with 5,000 DHHC3-ko sporozoites failed to develop blood-stage parasitemia and upon injection with 10,000 sporozoites, only one out of three mice developed a blood-stage infection, with a delay of three days compared to wild-type |
Additional remarks phenotype | Mutant/mutation/phenotype Reference PMID 27084458 In the same paper a double knock-out mutant is described lacking both DHHC3 and DHHC9 (PBANKA_0932100). This mutant shows a stronger reduction in oocyst and sporozoite production. In addition, ookinete development was affected (aberrant, shorter ookintes) with less than 1% normal mature ookinetes). |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_0927300 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1121000 | ||||||||||||||||||||||||
Gene product | palmitoyltransferase DHHC3 | ||||||||||||||||||||||||
Gene product: Alternative name | DHHC3 | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | (Linear) plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | Yes | ||||||||||||||||||||||||
Name of PlasmoGEM construct/vector | PbGEM-111866 | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Partial | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | |||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr/yfcu | ||||||||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | |||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |